약제 용출 스텐트 시장 규모, 점유율 및 동향 분석 보고서 : 코팅 유형별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Drug Eluting Stent Market Size & Trends:

The global drug eluting stent market size was estimated at USD 4.0 billion in 2025 and is projected to reach USD 6.7 billion by 2033, growing at a CAGR of 6.7% from 2026 to 2033. Market growth is primarily driven by the rising CVD prevalence, fueled by obesity, hypertension, diabetes, aging populations, sedentary lifestyles, and unhealthy diets. In October 2024, the CDC reported 919,032 deaths in the U.S. from cardiovascular disease in 2023, with coronary heart disease causing 371,506 deaths. About 1 in 6 CVD deaths occurred in adults under 65, and approximately 805,000 heart attacks happened nationwide, including 605,000 first-time events.

Rising Prevalence of Cardiovascular Diseases and Associated Risk Factors

The rising prevalence of cardiovascular diseases (CVDs) is a primary driver of the market. Increasing cases of coronary artery disease, heart failure, and peripheral artery disease are largely driven by lifestyle-related risk factors such as obesity, diabetes, hypertension, and sedentary behavior. As the global population ages, the demand for interventional procedures such as stenting, angioplasty, and catheter-based therapies continues to grow. In December 2025, the CDC released the 2024 adult obesity prevalence data for all U.S. states and territories. Obesity, defined as a BMI >=30 kg/m2, increases the risk of chronic diseases such as heart disease, diabetes, and certain cancers. Rates ranged from 25% to over 40%, highlighting the urgent need for prevention and treatment strategies across the population.

Increasing Volume of Percutaneous Coronary Intervention (PCI) Procedures

PCI is widely used to treat coronary artery disease and restore blood flow in narrowed or blocked coronary arteries. The increasing prevalence of cardiovascular diseases, including coronary artery disease and acute coronary syndromes, is raising the number of patients requiring interventional treatment. Higher incidence of risk factors such as hypertension, diabetes, and obesity further contributes to procedural demand. In May 2025, the SCAI Scientific Sessions reported that 408,060 outpatient PCI procedures (2020-2022) were analyzed, with 1.8% performed in ambulatory surgery centers and 98.2% in hospital outpatient departments. PCI use in ASCs rose to 0.87 per 10,000 person years, and 30 day adverse events, including mortality, stroke, and bleeding, remained below 2%.

Global Drug Eluting Stent Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global drug eluting stents market report based on type of coating, end use, and region:

• Type of Coating Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
• Polymer-based Coating
  • Non-biodegradable Polymers
  • Biodegradable Polymers
• Polymer-free Coating
  • Micro porous Surface
  • Micro structured Surface
  • Slotted tubular Surface
  • Nanoporous Surface
• End Use Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Cardiac/Vascular Centers
• Ambulatory Surgical Centers (ASCs)
• Regional Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
  • Indonesia
  • Malaysia
  • Vietnam
• Latin America
  • Brazil
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology And Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Scope
  • 1.1.2. Estimates And Forecast Timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
  • 1.3.5. Details Of Primary Research
• 1.4. Information Or Data Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Drug Eluting Stent Market: Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type of Coating Outlook
  • 2.2.2. End Use Outlook
• 2.3. Competitive Insights

Chapter 3. Drug Eluting Stent Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Market Opportunity Analysis
• 3.3. Global Drug Eluting Stents: Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Force Analysis
  • 3.3.2. PESTLE Analysis
• 3.4. Country-Level Market Driver Mapping
• 3.5. Market Entry Attractiveness Assessment

Chapter 4. Drug Eluting Stent Market Segment Analysis, By Type of Coating (Revenue in USD Million; Unit Volume in Thousand Units, 2021 - 2033)

• 4.1. Definition and Scope
• 4.2. Type of Coating Market Share Analysis, 2025 & 2033
• 4.3. Segment Dashboard
• 4.4. Global Drug Eluting Stents Market By Type of Coating Outlook
• 4.5. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For the Following
  • 4.5.1. Polymer-based Coating
    • 4.5.1.1. Polymer-based Coating Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.5.1.2. Polymer-based Coating Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
      • 4.5.1.2.1. Non-biodegradable Polymers
        • 4.5.1.2.1.1. Non-biodegradable Polymers Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 4.5.1.2.1.2. Non-biodegradable Polymers Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
      • 4.5.1.2.2. Biodegradable Polymers
        • 4.5.1.2.2.1. Biodegradable Polymers Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 4.5.1.2.2.2. Biodegradable Polymers Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 4.5.2. Polymer-free Coating
    • 4.5.2.1. Polymer-free Coating Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.5.2.2. Polymer-free Coating Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
      • 4.5.2.2.1. Micro Porous Surface
        • 4.5.2.2.1.1. Micro Porous Surface Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 4.5.2.2.1.2. Micro Porous Surface Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
      • 4.5.2.2.2. Micro Structured Surface
        • 4.5.2.2.2.1. Micro Structured Surface Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 4.5.2.2.2.2. Micro Structured Surface Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
      • 4.5.2.2.3. Slotted Tubular Surface
        • 4.5.2.2.3.1. Slotted Tubular Surface Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 4.5.2.2.3.2. Slotted Tubular Surface Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
      • 4.5.2.2.4. Nanoporous Surface
        • 4.5.2.2.4.1. Nanoporous Surface Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 4.5.2.2.4.2. Nanoporous Surface Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)

Chapter 5. Drug Eluting Stent Market Segment Analysis, By End Use 2021 - 2033 (USD Million)

• 5.1. Definition and Scope
• 5.2. End Use Market Share Analysis, 2025 & 2033
• 5.3. Segment Dashboard
• 5.4. Global Drug Eluting Stents Market By End Use Outlook
• 5.5. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For the Following
  • 5.5.1. Hospitals
    • 5.5.1.1. Hospitals Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 5.5.2. Specialty Cardiac/Vascular Centers
    • 5.5.2.1. Specialty Cardiac/Vascular Centers Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 5.5.3. Ambulatory Surgical Centers (ASCs)
    • 5.5.3.1. Ambulatory Surgical Centers (ASCs) Market Estimates and Forecasts 2021 To 2033 (USD Million)

Chapter 6. Drug Eluting Stent Market Segment Analysis, By Region, (Revenue in USD Million; Unit Volume in Thousand Units, 2021 - 2033)

• 6.1. Regional Market Share Analysis, 2025 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Drug Eluting Stents Market Share by Region, 2025 & 2033:
• 6.5. North America
  • 6.5.1. North America Drug Eluting Stents Market, 2021 - 2033 (USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. U.S. Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.5.2.5. U.S. Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.5.3. Canada
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Canada Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.5.3.5. Canada Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.5.4. Mexico
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Canada Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.5.4.5. Canada Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
• 6.6. Europe
  • 6.6.1. Europe Drug Eluting Stents Market, 2021 To 2033 (USD Million)
  • 6.6.2. UK
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. UK Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.6.2.5. UK Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.6.3. Germany
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Germany Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.6.3.5. Germany Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.6.4. France
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. France Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.6.4.5. France Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.6.5. Italy
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Competitive Scenario
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Italy Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.6.5.5. Italy Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.6.6. Spain
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Competitive Scenario
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Spain Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.6.6.5. Spain Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.6.7. Denmark
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Competitive Scenario
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Denmark Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.6.7.5. Denmark Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.6.8. Sweden
    • 6.6.8.1. Key Country Dynamics
    • 6.6.8.2. Competitive Scenario
    • 6.6.8.3. Regulatory Framework
    • 6.6.8.4. Sweden Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.6.8.5. Sweden Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.6.9. Norway
    • 6.6.9.1. Key Country Dynamics
    • 6.6.9.2. Competitive Scenario
    • 6.6.9.3. Regulatory Framework
    • 6.6.9.4. Norway Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.6.9.5. Norway Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
• 6.7. Asia Pacific
  • 6.7.1. China
    • 6.7.1.1. Key Country Dynamics
    • 6.7.1.2. Competitive Scenario
    • 6.7.1.3. Regulatory Framework
    • 6.7.1.4. China Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.7.1.5. China Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.7.2. Japan
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Japan Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.7.2.5. Japan Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.7.3. India
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. India Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.7.3.5. India Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.7.4. Australia
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. Australia Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.7.4.5. Australia Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.7.5. South Korea
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. South Korea Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.7.5.5. South Korea Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.7.6. Thailand
    • 6.7.6.1. Key Country Dynamics
    • 6.7.6.2. Competitive Scenario
    • 6.7.6.3. Regulatory Framework
    • 6.7.6.4. Thailand Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.7.6.5. Thailand Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.7.7. Indonesia
    • 6.7.7.1. Key Country Dynamics
    • 6.7.7.2. Competitive Scenario
    • 6.7.7.3. Regulatory Framework
    • 6.7.7.4. Indonesia Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.7.7.5. Indonesia Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.7.8. Malaysia
    • 6.7.8.1. Key Country Dynamics
    • 6.7.8.2. Competitive Scenario
    • 6.7.8.3. Regulatory Framework
    • 6.7.8.4. Malaysia Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.7.8.5. Malaysia Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.7.9. Vietnam
    • 6.7.9.1. Key Country Dynamics
    • 6.7.9.2. Competitive Scenario
    • 6.7.9.3. Regulatory Framework
    • 6.7.9.4. Vietnam Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.7.9.5. Vietnam Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
• 6.8. Latin America
  • 6.8.1. Latin America Drug Eluting Stents Market, 2021 - 2033 (USD Million)
  • 6.8.2. Brazil
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Brazil Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.8.2.5. Brazil Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.8.3. Argentina
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Argentina Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.8.3.5. Argentina Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.8.4. Colombia
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Competitive Scenario
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Colombia Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.8.4.5. Colombia Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.8.5. Chile
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Competitive Scenario
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Chile Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.8.5.5. Chile Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
• 6.9. MEA
  • 6.9.1. MEA Drug Eluting Stents Market, 2021 - 2033 (USD Million)
  • 6.9.2. South Africa
    • 6.9.2.1. Key Country Dynamics
    • 6.9.2.2. Competitive Scenario
    • 6.9.2.3. Regulatory Framework
    • 6.9.2.4. South Africa Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.9.2.5. South Africa Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.9.3. Saudi Arabia
    • 6.9.3.1. Key Country Dynamics
    • 6.9.3.2. Competitive Scenario
    • 6.9.3.3. Regulatory Framework
    • 6.9.3.4. Saudi Arabia Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.9.3.5. Saudi Arabia Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.9.4. UAE
    • 6.9.4.1. Key Country Dynamics
    • 6.9.4.2. Competitive Scenario
    • 6.9.4.3. Regulatory Framework
    • 6.9.4.4. UAE Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.9.4.5. UAE Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)
  • 6.9.5. Kuwait
    • 6.9.5.1. Key Country Dynamics
    • 6.9.5.2. Competitive Scenario
    • 6.9.5.3. Regulatory Framework
    • 6.9.5.4. Kuwait Drug Eluting Stents Market, 2021 To 2033 (USD Million)
    • 6.9.5.5. Kuwait Drug Eluting Stents Market Estimates and Forecasts 2021 To 2033 (Unit Volume, In Thousand Units)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company Categorization (Key innovators, market leaders, emerging players)
• 7.3. Company Market Position Analysis, 2025
• 7.4. Company Market Share Analysis, 2025/2026 (%)
• 7.5. Company Profiles
  • 7.5.1. Boston Scientific Corporation
    • 7.5.1.1. Company Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Medtronic
    • 7.5.2.1. Company Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Abbott
    • 7.5.3.1. Company Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Teleflex Incorporated (BIOTRONIK)
    • 7.5.4.1. Company Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Terumo Corporation
    • 7.5.5.1. Company Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. B. Braun SE
    • 7.5.6.1. Company Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Translumina
    • 7.5.7.1. Company Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. MicroPort Scientific Corporation
    • 7.5.8.1. Company Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Biosensors International Group, Ltd
    • 7.5.9.1. Company Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Lepu Medical
    • 7.5.10.1. Company Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. iVascular S.L.U.
    • 7.5.11.1. Company Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives
  • 7.5.12. SMT
    • 7.5.12.1. Company Overview
    • 7.5.12.2. Financial Performance
    • 7.5.12.3. Product Benchmarking
    • 7.5.12.4. Strategic Initiatives
  • 7.5.13. Meril Life Sciences Pvt. Ltd.
    • 7.5.13.1. Company Overview
    • 7.5.13.2. Financial Performance
    • 7.5.13.3. Product Benchmarking
    • 7.5.13.4. Strategic Initiatives
  • 7.5.14. Concept Medical
    • 7.5.14.1. Company Overview
    • 7.5.14.2. Financial Performance
    • 7.5.14.3. Product Benchmarking
    • 7.5.14.4. Strategic Initiatives
  • 7.5.15. Cardionovum GmbH
    • 7.5.15.1. Company Overview
    • 7.5.15.2. Financial Performance
    • 7.5.15.3. Product Benchmarking
    • 7.5.15.4. Strategic Initiatives